| Literature DB >> 33633797 |
Adi Lahat1, Zina Shatz2.
Abstract
BACKGROUND: The Coronavirus Disease 2019 pandemic has forced major changes on healthcare systems. Maintaining regular patients' surveillance became a major challenge. Telemedicine has been promoted as an economic and effective way for long distance patient care. Our aim was to study patients' acceptance and perspectives on telemedicine.Entities:
Keywords: COVID-19 pandemic; preference; satisfaction; telecare; telemedicine
Year: 2021 PMID: 33633797 PMCID: PMC7887676 DOI: 10.1177/1756284821989178
Source DB: PubMed Journal: Therap Adv Gastroenterol ISSN: 1756-283X Impact factor: 4.409
Patients’ characteristics.
| All | Sex | IBD | ||||
|---|---|---|---|---|---|---|
| Men | Women | No IBD | IBD | |||
|
| 59 | 24 | 35 | 21 | 38 | |
| Age, years | Mean | 43.44 | 45.13 | 42.29 | 47.14 | 41.39 |
| Median | 40.00 | 40.00 | 43.00 | 48.00 | 39.50 | |
| Standard deviation | 16.33 | 18.88 | 14.51 | 19.35 | 14.27 | |
| Minimum | 19.0 | 20.0 | 19.0 | 19.0 | 20.0 | |
| Maximum | 76.0 | 76.0 | 70.0 | 76.0 | 69.0 | |
|
| 0.616 | 0.278 | ||||
| Follow-up, years | Mean | 4.04 | 3.71 | 4.27 | 2.62 | 4.83 |
| Median | 3.0 | 3.0 | 3.0 | 2.0 | 4.5 | |
| Standard deviation | 2.96 | 2.71 | 3.14 | 2.06 | 3.11 | |
| Minimum | 1.0 | 0.5 | 0.5 | 1.0 | 1.0 | |
| Maximum | 15.0 | 9.0 | 15.0 | 8.0 | 15.0 | |
|
| 0.51 | 0.003 | ||||
IBD, inflammatory bowel disease.
Summary of telecare disadvantages reported by patients.
| Disadvantage | No. of confirmative answers | Percentage |
|---|---|---|
| Not effective | 2 | 4.65 |
| Cannot show documents | 4 | 9.30 |
| No meeting summary | 2 | 4.65 |
| Poor communication | 1 | 2.33 |
| Uncomfortable providing personal information over the phone | 2 | 4.65 |
| No physical examination | 30 | 69.77 |
| No reminder for appointment | 1 | 2.33 |
| Not personal | 1 | 2.33 |
| Total | 43 | 100 |
Total satisfaction score adjusted to follow-up period.
| Model 1 | Unstandardized coefficients | Standardized coefficients |
| Sig. | 95% confidence interval for B | ||
|---|---|---|---|---|---|---|---|
| B | Standard error | Beta | Lower bound | Upper bound | |||
| (Constant) | 84.685 | 9.336 | 9.070 | 0.000 | 65.975 | 103.396 | |
| Sex | 4.794 | 4.231 | 0.145 | 1.133 | 0.262 | –3.686 | 13.274 |
| Age, years | –0.158 | 0.130 | –0.157 | –1.209 | 0.232 | –0.419 | 0.104 |
| Follow-up period (years) | –1.292 | 0.720 | –0.234 | –1.795 | 0.078 | –2.734 | 0.150 |
Total satisfaction score adjusted to IBD diagnosis.
| Model 2 | Unstandardized coefficients | Standardized coefficients |
| Sig. | 95% confidence interval for B | ||
|---|---|---|---|---|---|---|---|
| B | Standard error | Beta | Lower bound | Upper bound | |||
| (Constant) | 84.951 | 10.227 | 8.307 | 0.000 | 64.456 | 105.446 | |
| Sex | 3.976 | 4.314 | 0.121 | 0.922 | 0.361 | –4.670 | 12.622 |
| Age, years | –0.217 | 0.133 | –0.217 | –1.637 | 0.107 | –0.483 | 0.049 |
| IBD diagnosis | –2.461 | 4.475 | –0.073 | –0.550 | 0.585 | –11.429 | 6.508 |
IBD, inflammatory bowel disease.